Authors' objectives: Renal denervation is used to control blood pressure in patients with resistant hypertension. The objective of this report is to summarize the literature on efficacy, effectiveness and safety of renal denervation for treatment of resistant hypertension, and to estimate the budget impact of this technology from the perspective of the MUHC.

Authors' recommendations: It is recommended that this technology receive temporary and conditional approval as follows: There is agreement by the applicant and the divisional head that this technology be only applied in the context of a formal research study designed to further evaluate its efficacy or effectiveness and safety. The study should meet associated requirements of ethics committee approval and informed consent of subjects. Although this research is partly sponsored by the manufacturer, the applicant should retain the rights of publication of any data generated. Renal denervation procedures should be limited to a maximum of 20 per year and subsidized by the manufacturer as indicated above. The question of permanent approval be reconsidered at a maximum of two years after the first procedure is completed.

Project Status: Completed

Year Published: 2013

URL for published report: http://www.mcgill.ca/tau/files/tau/muhc_tau_2013_72_renald.pdf

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Canada

Organisation Name: Technology Assessment Unit of the McGill University Health Centre (MUHC)

Contact Address: Technology Assessment Unit of the MUHC, Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve, Bureau 3F.50, Montreal, Quebec H4A 3S5

Contact Name: nandini.dendukuri@mcgill.ca

Contact Email: nandini.dendukuri@mcgill.ca

Copyright: <p>Technology Assessment Unit of the McGill University Health Centre (MUHC)</p>